Contracts › 75N93023P00594
75N93023P00594: Yearly License (Maintenance Fee and Ind Filing Fee) to Use a Monoclonal Antibody Produced Via Atum Proprietary Cell Line Technology
Awarded to Dna Twopointo Inc. by National Institutes of Health (NIH).
$300Kobligated
$375Kpotential value
13 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023P00594 |
|---|---|
| Awardee | Dna Twopointo Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 325414 Biological Product (Except Diagnostic) Manufacturing |
| PSC | 6505 Drugs and Biologicals |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 14 May 2023 to 13 May 2027 |
| Potential end | 13 May 2028 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 325414 contracts · All expiring contracts · USASpending record